These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 21780334

  • 1. Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease.
    White CM, Greene L.
    J Manag Care Pharm; 2011 Jun; 17(5 Suppl):S1-15. PubMed ID: 21780334
    [Abstract] [Full Text] [Related]

  • 2. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease.
    Baker WL, Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R, Phung OJ, White CM.
    Ann Intern Med; 2009 Dec 15; 151(12):861-71. PubMed ID: 20008762
    [Abstract] [Full Text] [Related]

  • 3. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
    Powers B, Greene L, Balfe LM.
    J Manag Care Pharm; 2011 Oct 15; 17(8 Suppl):S1-14. PubMed ID: 22088101
    [Abstract] [Full Text] [Related]

  • 4. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T.
    Am J Cardiol; 2003 May 22; 91(10A):28G-34G. PubMed ID: 12781906
    [Abstract] [Full Text] [Related]

  • 5. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H, ONTARGET/TRANSCEND Investigators.
    Am Heart J; 2004 Jul 22; 148(1):52-61. PubMed ID: 15215792
    [Abstract] [Full Text] [Related]

  • 6. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
    Yusuf S.
    Am J Cardiol; 2002 Jan 24; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
    [Abstract] [Full Text] [Related]

  • 7. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C, Pöss J, Böhm M.
    Drugs; 2010 Jul 09; 70(10):1215-30. PubMed ID: 20568830
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
    Li EC, Heran BS, Wright JM.
    Cochrane Database Syst Rev; 2014 Aug 22; 2014(8):CD009096. PubMed ID: 25148386
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF, ONTARGET and TRANSCEND Investigators.
    Circulation; 2011 Mar 15; 123(10):1098-107. PubMed ID: 21357827
    [Abstract] [Full Text] [Related]

  • 10. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C.
    Ther Adv Cardiovasc Dis; 2008 Aug 15; 2(4):233-48. PubMed ID: 19124424
    [Abstract] [Full Text] [Related]

  • 11. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Böhm M, Baumhäkel M, Mahfoud F, Werner C.
    Cardiology; 2010 Aug 15; 117(3):163-73. PubMed ID: 21051889
    [Abstract] [Full Text] [Related]

  • 12. Recent advances in cardiovascular risk reduction: implications of ONTARGET.
    Guthrie R.
    Clin Cornerstone; 2009 Aug 15; 9 Suppl 3():S18-26. PubMed ID: 19409352
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
    Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B.
    PLoS Med; 2016 Mar 15; 13(3):e1001971. PubMed ID: 26954482
    [Abstract] [Full Text] [Related]

  • 20. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV, Dass EE.
    Indian J Pharmacol; 2015 Mar 15; 47(2):148-52. PubMed ID: 25878372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.